Biotech Values

[DewDiligence]

AVIR—Phase-2 condyloma trial delayed—data now expected 2H17 (h/t @bio_clouseau):

https://www.sec.gov/Archives/edgar/data/72444/000143774916031390/bota20160331_10q.htm (p16)

Dosed first subject in a Phase 2 double-blind, randomized, placebo-controlled trial to evaluate the safety, tolerability and efficacy of BTA074 5% gel in male and female patients with condyloma, or anogenital warts, caused by human papillomavirus (“HPV”) types 6 & 11.

A delay in the availability of clinical trial material required to resupply the initial clinical sites is expected to result in a delay in the availability of top-line data of the trial until the second half of 2017. To minimize the delay, we are in the process of identifying new clinical sites for participation in the Phase 2 trial.

I’m not sure what the prior guidance was.